![]() |
| Photo Credit: Louis Reed |
The two-pronged attack of a “forgotten drug” simultaneously targets two cancer-causing pathways of leukemia to stop the disease in its tracks
A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore, led by Associate Professor Takaomi Sanda and Dr Lim Fang Qi, has breathed new life into an existing drug — combatting a type of blood cancer called T-cell acute lymphoblastic leukemia, or T-ALL.
The drug, called PIK-75, was initially discovered over a decade ago but was dismissed in favor of newer ones. Now, it has made a comeback that deems it unmissable — the researchers established that the drug could block not just one but two crucial cancer-causing pathways of T-ALL, enabling them to develop new treatments that could effectively stem the disease.



.jpg)


.jpg)


.jpg)




